{"transactions":[{"id":731754,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-18T20:30:24.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":1065000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 1,065,000 restricted stock units on June 16, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully\nvested, provided that the Reporting Person remains in service with the Issuer through each such vesting date."}],"balance_after":1759183,"source":{"system":"sec-edgar","filing":"0001104659-26-075773","document":"tm2618312-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926075773/tm2618312-1_4seq1.xml","form_type":"4"}},{"id":978800,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-12-05T21:05:13.000Z","date":"2025-12-03","kind":"other","planned":false,"acquired":false,"shares":187066,"price":1.5,"value":280599.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the \"Issuer\") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs."}],"balance_after":686966,"source":{"system":"sec-edgar","filing":"0001104659-25-118872","document":"tm2532693-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465925118872/tm2532693-1_4seq1.xml","form_type":"4"}},{"id":1303225,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T22:34:30.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":385750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 10, 2025 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":385750,"derivative":{"exercise_price":0.9525,"expiration_date":"2035-01-10","underlying":"Common Stock","underlying_shares":385750},"source":{"system":"sec-edgar","filing":"0001104659-25-003501","document":"tm253166-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465925003501/tm253166-7_4seq1.xml","form_type":"4"}},{"id":1303224,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-14T22:34:30.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":243900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The Reporting Person received an award of 243,900 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, provided that the Reporting Person remains in service with the Issuer through each such vesting date."}],"balance_after":859032,"source":{"system":"sec-edgar","filing":"0001104659-25-003501","document":"tm253166-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465925003501/tm253166-7_4seq1.xml","form_type":"4"}},{"id":1303223,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-14T22:34:30.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":257000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 257,000 restricted stock units on January 10, 2025, which shall vest as follows: (i) 25% on December 1, 2025 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date."}],"balance_after":615132,"source":{"system":"sec-edgar","filing":"0001104659-25-003501","document":"tm253166-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465925003501/tm253166-7_4seq1.xml","form_type":"4"}},{"id":1341389,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-05T22:05:44.000Z","date":"2024-12-04","kind":"other","planned":false,"acquired":false,"shares":28289,"price":1.13,"value":31966.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction relates to shares of common stock withheld by the SELLAS Life Sciences Group, Inc. (the \"Issuer\") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs."}],"balance_after":358132,"source":{"system":"sec-edgar","filing":"0001104659-24-125943","document":"tm2430303-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924125943/tm2430303-2_4seq1.xml","form_type":"4"}},{"id":1670717,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-25T11:04:41.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":238500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 22, 2024 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":238500,"derivative":{"exercise_price":0.5195,"expiration_date":"2034-01-22","underlying":"Common Stock","underlying_shares":238500},"source":{"system":"sec-edgar","filing":"0001104659-24-006410","document":"tm243935-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924006410/tm243935-5_4seq1.xml","form_type":"4"}},{"id":1670716,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-25T11:04:41.000Z","date":"2024-01-22","kind":"grant","planned":false,"acquired":true,"shares":159000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 159,000 restricted stock units on January 22, 2024, which shall vest as follows: (i) 25% on December 1, 2024 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date."}],"balance_after":376421,"source":{"system":"sec-edgar","filing":"0001104659-24-006410","document":"tm243935-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465924006410/tm243935-5_4seq1.xml","form_type":"4"}},{"id":1717562,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2023-12-08T21:10:53.000Z","date":"2023-12-06","kind":"other","planned":false,"acquired":false,"shares":12268,"price":1.08,"value":13249.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction relates to shares of common stock withheld by SELLAS Life Sciences Group, Inc. (the \"Issuer\") to cover tax withholding obligations of the Reporting Person in connection with the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number shares of common stock withheld by the Issuer to cover tax withholding obligations of the Reporting Person in connection with the vesting of RSUs."}],"balance_after":217421,"source":{"system":"sec-edgar","filing":"0001104659-23-124688","document":"tm2332459-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923124688/tm2332459-3_4seq1.xml","form_type":"4"}},{"id":2032349,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T22:15:39.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":217500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the February 2, 2023 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":217500,"derivative":{"exercise_price":3.34,"expiration_date":"2033-02-02","underlying":"Common Stock","underlying_shares":217500},"source":{"system":"sec-edgar","filing":"0001104659-23-010638","document":"tm235353d7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923010638/tm235353d7_4seq1.xml","form_type":"4"}},{"id":2032348,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-03T22:15:39.000Z","date":"2023-02-02","kind":"grant","acquired":true,"shares":58000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 58,000 restricted stock units on February 2, 2023, which shall vest as follows: (i) 25% on December 1, 2023 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.date."}],"balance_after":219689,"source":{"system":"sec-edgar","filing":"0001104659-23-010638","document":"tm235353d7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923010638/tm235353d7_4seq1.xml","form_type":"4"}},{"id":2095703,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Class A Common Stock","published_at":"2022-12-05T21:14:34.000Z","date":"2022-12-05","kind":"sale","acquired":false,"shares":6494,"price":2.6083,"value":16938.3002,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reflects the weighted average sale price of the shares of common stock sold. These shares of common stock were sold in multiple transactions at prices ranging from $2.58 to $2.66, inclusive, per share of common stock. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares of common stock sold at each price."}],"balance_after":161689,"source":{"system":"sec-edgar","filing":"0001104659-22-124568","document":"tm2232008-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465922124568/tm2232008-3_4seq1.xml","form_type":"4"}},{"id":2418899,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-01T22:06:24.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":165000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the January 31, 2022 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":165000,"derivative":{"exercise_price":5.34,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":165000},"source":{"system":"sec-edgar","filing":"0001104659-22-010396","document":"tm225088-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465922010396/tm225088-3_4seq1.xml","form_type":"4"}},{"id":2418898,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-02-01T22:06:24.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 44,000 restricted stock units on January 31, 2022, which shall vest as follows: (i) 25% on December 1, 2022 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date."}],"balance_after":165167,"source":{"system":"sec-edgar","filing":"0001104659-22-010396","document":"tm225088-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465922010396/tm225088-3_4seq1.xml","form_type":"4"}},{"id":2485192,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-12-03T22:15:02.000Z","date":"2021-12-02","kind":"sale","acquired":false,"shares":2120,"price":6.2509,"value":13251.908,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs.  The sale was to satisfy tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reflects the weighted average sale price of the shares of common stock sold. These shares of common stock were sold in multiple transactions at prices ranging from $6.25 to $6.27, inclusive, per share of common stock. The Reporting Person undertakes to provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares of common stock sold at each price."}],"balance_after":121167,"source":{"system":"sec-edgar","filing":"0001104659-21-146424","document":"tm2134552-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465921146424/tm2134552-6_4seq1.xml","form_type":"4"}},{"id":2802659,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-08T21:26:50.000Z","date":"2021-03-04","kind":"grant","acquired":true,"shares":118500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 4, 2021 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":118500,"derivative":{"exercise_price":8,"expiration_date":"2031-03-04","underlying":"Common Stock","underlying_shares":118500},"source":{"system":"sec-edgar","filing":"0001104659-21-033287","document":"tm218923-1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465921033287/tm218923-1_4.xml","form_type":"4"}},{"id":2802658,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-08T21:26:50.000Z","date":"2021-03-04","kind":"grant","acquired":true,"shares":19750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person received an award of 19,750 restricted stock units on March 4, 2021, which shall vest as follows: (i) 25% on December 1, 2021 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date."}],"balance_after":98287,"source":{"system":"sec-edgar","filing":"0001104659-21-033287","document":"tm218923-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465921033287/tm218923-1_4.xml","form_type":"4"}},{"id":3208309,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-17T01:18:52.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 12, 2020 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.89,"expiration_date":"2030-03-12","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001104659-20-034286","document":"tm2012902-3_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465920034286/tm2012902-3_form4.xml","form_type":"4"}},{"id":3208308,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-17T01:18:52.000Z","date":"2020-03-12","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person received an award of 95,000 restricted stock units on March 12, 2020, which shall vest as follows: (i) 50% on meeting the primary endpoint in Phase 3 REGAL study, provided that if such endpoint is met prior to March 12, 2021, such vesting will not occur until March 12, 2021 and (ii) 50% upon approval by the FDA of galinpepimut-S."}],"balance_after":95000,"source":{"system":"sec-edgar","filing":"0001104659-20-034286","document":"tm2012902-3_form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000110465920034286/tm2012902-3_form4.xml","form_type":"4"}},{"id":3590100,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-18T23:02:24.000Z","date":"2019-03-14","kind":"grant","acquired":true,"shares":425000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 14, 2019 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":425000,"derivative":{"exercise_price":1.38,"expiration_date":"2029-03-14","underlying":"Common Stock","underlying_shares":425000},"source":{"system":"sec-edgar","filing":"0000899243-19-008199","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000089924319008199/doc4.xml","form_type":"4"}},{"id":3707647,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2019-01-04T02:03:04.000Z","date":"2018-12-31","kind":"sale","acquired":false,"shares":23277,"price":1.254,"value":29189.358,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person sold such shares to cover personal income tax liability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold at prices ranging from $1.23 to $1.31 The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":426858,"source":{"system":"sec-edgar","filing":"0001209191-19-001612","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000120919119001612/doc4.xml","form_type":"4"}},{"id":3994288,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Angelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-03-15T23:56:48.000Z","date":"2018-03-13","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 13, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date."}],"balance_after":95000,"derivative":{"exercise_price":5.24,"expiration_date":"2028-03-12","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-18-020013","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000120919118020013/doc4.xml","form_type":"4"}},{"id":4118837,"issuer":{"id":4313,"kind":"organization","name":"SELLAS Life Sciences Group, Inc."},"owners":[{"id":36721,"kind":"person","name":"Stergiou Angelos M.","position":1,"cik":"0001724253","reported_name":"Stergiou Andelos M.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-12-29T22:12:26.000Z","date":"2017-12-29","kind":"grant","acquired":true,"shares":450135,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for common shares of SELLAS Life Sciences Group, Ltd (\"SELLAS\") in connection with the merger of SELLAS and a wholly owned indirect subsidiary of Issuer (then known as Galena Biopharma, Inc.) (the \"Merger\").  On the effective date of the Merger, each common share of SELLAS was converted into 43.9972 shares of the Issuer's common stock."}],"balance_after":450135,"source":{"system":"sec-edgar","filing":"0001209191-17-067660","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1390478/000120919117067660/doc4.xml","form_type":"4"}}]}